专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20110217719A1 METHODS AND KITS FOR DIAGNOSING OBSTRUCTIVE SLEEP APNEA 有权
标题翻译：用于诊断阻塞性睡眠APNEA的方法和工具
公开(公告)号：US20110217719A1
公开(公告)日：2011-09-08
申请号：US13121037
申请日：2009-09-25
申请人： David Gozal , Saeed A. Jortani , Roland Valdes, JR. , Leila Kheirandish-Gozal
发明人： David Gozal , Saeed A. Jortani , Roland Valdes, JR. , Leila Kheirandish-Gozal
IPC分类号： G01N33/68 , C12Q1/37 , G01N33/573 , H01J49/26
CPC分类号： G01N33/6896 , G01N2800/2864
摘要： The presently-disclosed subject matter provides methods and kits for diagnosing obstructive sleep apnea (OSA) in a subject, such as a human child, wherein a biological sample is provided from the subject and the amount of a Urocortin III peptide is determined from the sample. Further provided are methods for diagnosing OSA in a subject wherein the amount of a Urocortin III peptide and one or more peptides selected from a Uromodulin peptide, an Orosomucoid 1 peptide, and a Kallikrein 1 peptide are determined in a biological sample from a subject.
摘要翻译：目前公开的主题提供了用于诊断受试者例如人类小孩的阻塞性睡眠呼吸暂停（OSA）的方法和试剂盒，其中从受试者提供生物样品，并从样品中确定Urocortin III肽的量。还提供了用于诊断受试者中的OSA的方法，其中在来自受试者的生物样品中测定Urocortin III肽和选自Uromodulin肽，Orosomuroid 1肽和激肽释放酶1肽的一种或多种肽的量。

2. 发明授权

US08999658B2 Methods and kits for diagnosing obstructive sleep apnea 有权
标题翻译：用于诊断阻塞性睡眠呼吸暂停的方法和试剂盒
公开(公告)号：US08999658B2
公开(公告)日：2015-04-07
申请号：US13121037
申请日：2009-09-25
申请人： David Gozal , Saeed A. Jortani , Roland Valdes, Jr. , Leila Kheirandish-Gozal
发明人： David Gozal , Saeed A. Jortani , Roland Valdes, Jr. , Leila Kheirandish-Gozal
IPC分类号： G01N33/68 , G01N33/573 , C12Q1/37 , H01J49/26
CPC分类号： G01N33/6896 , G01N2800/2864
摘要： The presently-disclosed subject matter provides methods and kits for diagnosing obstructive sleep apnea (OSA) in a subject, such as a human child, wherein a biological sample is provided from the subject and the amount of a Urocortin III peptide is determined from the sample. Further provided are methods for diagnosing OSA in a subject wherein the amount of a Urocortin III peptide and one or more peptides selected from a Uromodulin peptide, an Orosomucoid 1 peptide, and a Kallikrein 1 peptide are determined in a biological sample from a subject.
摘要翻译：目前公开的主题提供了用于诊断受试者例如人类小孩的阻塞性睡眠呼吸暂停（OSA）的方法和试剂盒，其中从受试者提供生物样品，并从样品中确定Urocortin III肽的量。还提供了用于诊断受试者中的OSA的方法，其中在来自受试者的生物样品中测定Urocortin III肽和选自Uromodulin肽，Orosomuroid 1肽和激肽释放酶1肽的一种或多种肽的量。

3. 发明申请

US20110177000A1 Use of S-Nitrosothiol Signaling to Treat Disordered Control of Breathing 审中-公开
标题翻译：使用S-亚硝基硫酚信号来控制呼吸的无序控制
公开(公告)号：US20110177000A1
公开(公告)日：2011-07-21
申请号：US13072979
申请日：2011-03-28
申请人： Benjamin M. Gaston , David Gozal
发明人： Benjamin M. Gaston , David Gozal
IPC分类号： A61K49/00 , A61K31/21 , A61K38/06 , A61K38/05 , A61K31/198 , A61K33/00 , A61P11/00
CPC分类号： A61K31/21 , A61K31/00
摘要： The present invention is directed to a method of treating disordered control of breathing including the treatment of apnea and hypoventilation associated with congenital or acquired brain stem abnormalities. Specifically the invention is directed to treating disordered control of breathing by administering an S-nitrosylating agent selected from the group consisting of ethylnitrite, glutathione, nitric oxide, S-nitrosocysteine, S-nitrosoglutathione, S-nitroso-L-cysteinyl glycine, N-acetyl cysteine and S-nitroso-N-acetyl cysteine. As shown in FIG. 1C the ability of endogenous SNOs to increase VE in freely behaving, conscious rats using whole-body plethysmography revealed that CSNO, GSNO and CGSNO (1 nmol each) caused equivalent increases in VE, whereas D-CSNO had no effect (left bar graph is the control whereas the right bar represents administration of the respective SNO).
摘要翻译：本发明涉及一种治疗无序呼吸控制的方法，包括治疗与先天性或获得性脑干异常相关的呼吸暂停和通气不足。具体地说，本发明涉及通过施用选自亚硝酸亚乙酯，谷胱甘肽，一氧化氮，S-亚硝基半胱氨酸，S-亚硝基谷胱甘肽，S-亚硝基-L-半胱氨酰甘氨酸，N-亚硝基半胱氨酸甘氨酸，乙酰半胱氨酸和S-亚硝基-N-乙酰半胱氨酸。如图所示。 1C使用全身体积描记法观察内源性SNO增加自由行为意识的大鼠VE的能力，揭示了CSNO，GSNO和CGSNO（各1 nmol）引起VE等效增加，而D-CSNO没有作用（左柱状图为对照，而右栏表示相应SNO的施用）。

4. 发明申请

US20110166114A1 METHOD FOR TREATING SNORING AND SLEEP APNEA WITH LEUKOTRIENE ANTAGONISTS 审中-公开
标题翻译：用紫外线拮抗剂处理SN ING AND。。。。。。。。。。。。。。。。。。。。
公开(公告)号：US20110166114A1
公开(公告)日：2011-07-07
申请号：US13047676
申请日：2011-03-14
申请人： David Gozal
发明人： David Gozal
IPC分类号： A61K31/58 , A61K31/47 , A61K31/4045 , A61K31/41 , A61K31/573 , A61P11/00
CPC分类号： A61K31/192 , A61K31/352 , A61K31/404 , A61K31/41 , A61K31/47
摘要： A method of treating snoring and/or sleep apnea comprising administering to a patient in need of such treatment a therapeutically effective amount of a leukotriene receptor antagonist.
摘要翻译：一种治疗打鼾和/或睡眠呼吸暂停的方法，包括向需要这种治疗的患者施用治疗有效量的白细胞三烯受体拮抗剂。

5. 发明申请

US20060194840A1 Method for treating snoring and sleep apnea with leukotriene antagonists 审中-公开
标题翻译：用白细胞三烯拮抗剂治疗打鼾和睡眠呼吸暂停的方法
公开(公告)号：US20060194840A1
公开(公告)日：2006-08-31
申请号：US11385583
申请日：2006-03-20
申请人： David Gozal
发明人： David Gozal
IPC分类号： A61K31/47
CPC分类号： A61K31/192 , A61K31/352 , A61K31/404 , A61K31/41 , A61K31/47
摘要： A method of treating snoring and/or sleep apnea comprising administering to a patient in need of such treatment a therapeutically effective amount of a leukotriene receptor antagonist.
摘要翻译：一种治疗打鼾和/或睡眠呼吸暂停的方法，包括向需要这种治疗的患者施用治疗有效量的白细胞三烯受体拮抗剂。

6. 发明申请

US20090004298A1 Use of S-Nitrosothiol Signaling to Treat Disordered Control of Breathing 审中-公开
标题翻译：使用S-亚硝基硫酚信号来控制呼吸的无序控制
公开(公告)号：US20090004298A1
公开(公告)日：2009-01-01
申请号：US12207042
申请日：2008-09-09
申请人： Benjamin M. Gaston , David Gozal
发明人： Benjamin M. Gaston , David Gozal
IPC分类号： A61K33/00 , A61K31/045 , A61K38/06 , A61P11/00 , A61K31/195 , A61K31/198
CPC分类号： A61K31/21 , A61K31/00
摘要： The present invention is directed to a method of treating disordered control of breathing including the treatment of apnea and hypoventilation associated with congenital or acquired brain stem abnormalities. Specifically the invention is directed to treating disordered control of breathing by administering an S-nitrosylating agent selected from the group consisting of ethyl nitrite, glutathione, nitric oxide, S-nitrosocysteine, S-nitrosoglutathione, S-nitroso-L-cysteinyl glycine, N-acetyl cysteine and S-nitroso-N-acetyl cysteine. As shown in FIG. 1C the ability of endogenous SNOs to increase VE in freely behaving, conscious rats using whole-body plethysmography revealed that CSNO, GSNO and CGSNO (1 nmol each) caused equivalent increases in VE, whereas D-CSNO had no effect (left bar graph is the control whereas the right bar represents administration of the respective SNO).
摘要翻译：本发明涉及一种治疗无序呼吸控制的方法，包括治疗与先天性或获得性脑干异常相关的呼吸暂停和通气不足。具体地说，本发明涉及通过施用选自亚硝酸乙酯，谷胱甘肽，一氧化氮，S-亚硝基半胱氨酸，S-亚硝基谷胱甘肽，S-亚硝基-L-半胱氨酰甘氨酸，N 乙酰半胱氨酸和S-亚硝基-N-乙酰半胱氨酸。如图所示。 1C使用全身体积描记法观察内源性SNO增加自由行为意识的大鼠VE的能力，揭示了CSNO，GSNO和CGSNO（各1 nmol）引起VE等效增加，而D-CSNO没有作用（左柱状图为对照，而右栏表示相应SNO的施用）。

7. 发明授权

US07432301B2 Use of S-nitrosothiol signaling to treat disordered control of breathing 有权
标题翻译：使用S-亚硝基硫醇信号来治疗呼吸紊乱的控制
公开(公告)号：US07432301B2
公开(公告)日：2008-10-07
申请号：US10487060
申请日：2002-08-12
申请人： Benjamin M. Gaston , David Gozal
发明人： Benjamin M. Gaston , David Gozal
IPC分类号： A61K38/00 , A61K38/05 , A61K38/06 , A61K31/04
CPC分类号： A61K31/21 , A61K31/00
摘要： The present invention is directed to a method of treating disordered control of breathing including the treatment of apnea and hypoventilation associated with congenital or acquired brain stem abnormalities. Specifically the invention is directed to treating disordered control of breathing by administering an S-nitrosylating agent selected from the group consisting of ethyl nitrite, glutathione, nitric oxide, S-nitrosocysteine, S-nitrosoglutathione, S-nitro-N-acetyl cysteine. As shown in FIG. 1C the ability of endogenous SNOg to increase VE in freely behaving, conscious rates using whole-body plethysmography revealed that CSNO, GSNO and CGSNO (1 nmol each) caused equivalent increases in VE, whereas D-CSNO had no effect (left bar graph is the equivalent increases in VE, whereas D-CSNO had no effect (left bar graph is the control whereas the right bar represents administration of the respective SNO).
摘要翻译：本发明涉及一种治疗无序呼吸控制的方法，包括治疗与先天性或获得性脑干异常相关的呼吸暂停和通气不足。具体地，本发明涉及通过施用选自亚硝酸乙酯，谷胱甘肽，一氧化氮，S-亚硝基半胱氨酸，S-亚硝基谷胱甘肽，S-硝基-N-乙酰半胱氨酸的S-亚硝基化剂来治疗无意义的呼吸控制。如图所示。使用全身体积描记法，内源性SNO 以自由行为意识率增加V E E的能力显示，CSNO，GSNO和CGSNO（各1nmol）引起 V-E的等效增加，而D-CSNO没有影响（左条形图是V E E的等效增加，而D-CSNO没有影响（左条形图是对照，而右栏表示相应SNO的施用）。

8. 发明申请

US20060029980A1 Method for diagnosing obstructive sleep apnea 审中-公开
标题翻译：阻塞性睡眠呼吸暂停诊断方法
公开(公告)号：US20060029980A1
公开(公告)日：2006-02-09
申请号：US11199355
申请日：2005-08-08
申请人： David Gozal , Saeed Jortani , Roland Valdes
发明人： David Gozal , Saeed Jortani , Roland Valdes
IPC分类号： G01N33/53
CPC分类号： G01N33/6848 , G01N2333/4728 , G01N2333/723 , G01N2333/78 , G01N2333/96455 , G01N2550/00 , G01N2800/2864
摘要： A method for diagnosing obstructive sleep apnea in a patient comprises identifying at least one protein biomarker for obstructive sleep apnea; obtaining a sample from the patient; and testing the sample for presence of the at least one protein biomarker. The protein biomarkers may include alpha-1 B-glycoprotein; kallikrein, laminin, aldosterone-binding protein and/or urocortin-2 precursor. The presence of the protein biomarkers may be detected using antibodies. These antibodies may be provided in an array for detecting the presence of the at least one protein biomarker or a pattern of protein biomarkers.
摘要翻译：用于诊断患者阻塞性睡眠呼吸暂停的方法包括鉴定至少一种用于阻塞性睡眠呼吸暂停的蛋白质生物标志物; 从患者身上获取样本; 并测试所述样品以存在所述至少一种蛋白质生物标志物。蛋白质生物标志物可以包括α-1B-糖蛋白; 激肽释放酶，层粘连蛋白，醛固酮结合蛋白和/或尿皮质素2前体。可以使用抗体检测蛋白质生物标志物的存在。这些抗体可以以用于检测至少一种蛋白质生物标志物的存在或蛋白质生物标记物的形式的阵列提供。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式